Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enanta PharmaceuticalsSTU:9EP 58 Quick Ratio is 3.84 as of Mar. 2026, which is 70% below its 10-year median of 12.61. GuruFocus rates STU:9EP with a GF Score™ of 58/100 and a GF Value™ of €7.73 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,411 Biotechnology companies, Enanta Pharmaceuticals ranks better than 51.74% on this metric.
Enanta Pharmaceuticals has a quick ratio of 3.84. It generally indicates good short-term financial strength.
The historical rank and industry rank for Enanta Pharmaceuticals's Quick Ratio or its related term are showing as below:
STU:9EP'
s Quick Ratio Range Over the Past 10 Years
Min: 3.84 Med: 12.61 Max: 34.84
Current: 3.84
During the past 13 years, Enanta Pharmaceuticals's highest Quick Ratio was 34.84. The lowest was 3.84. And the median was 12.61.
STU:9EP's Quick Ratio is ranked better than 51.74% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs STU:9EP: 3.84
Enanta Pharmaceuticals (STU:9EP) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Enanta Pharmaceuticals Quick Ratio Related Terms
Enanta Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:9EP vs PBYI, IPSC, BNTC: Quick Ratio Comparison
For the Biotechnology subindustry, Enanta Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enanta Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Enanta Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Enanta Pharmaceuticals's Quick Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enanta Pharmaceuticals (STU:9EP) has a Quick Ratio of 3.84 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Enanta Pharmaceuticals and its competitors. This is 70% below median its historical median of 12.61. Over the past decade, Enanta Pharmaceuticals' Quick Ratio has ranged from 3.84 to 34.84. According to the industry distribution chart, Enanta Pharmaceuticals ranks #681 out of 1411 companies in the Biotechnology industry, placing it in the top 48.3%.
Is Enanta Pharmaceuticals' Quick Ratio too high?
Enanta Pharmaceuticals' current Quick Ratio of 3.84 is 70% below median its 10-year median of 12.61. Over the past 10 years, this metric has ranged from a low of 3.84 to a high of 34.84. The Biotechnology industry median Quick Ratio is 3.59. Enanta Pharmaceuticals' value of 3.84 is 7% above this industry median. Based on the distribution chart, Enanta Pharmaceuticals ranks #681 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Quick Ratio compare to PBYI and IPSC?
According to the Biotechnology industry distribution chart, Enanta Pharmaceuticals ranks #681 out of 1411 companies for Quick Ratio. This puts Enanta Pharmaceuticals in the upper half of its industry. The industry median Quick Ratio is 3.59. Enanta Pharmaceuticals' value of 3.84 is 7% above this benchmark. Historically, Enanta Pharmaceuticals' own Quick Ratio has ranged from 3.84 to 34.84 over the past decade. While the company's 10-year median is 12.61 vs. the industry median of 3.59, Enanta Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enanta Pharmaceuticals's current Quick Ratio of 3.84 is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Enanta Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enanta Pharmaceuticals's current Quick Ratio is 3.84, which is 70% below median its own 10-year median of 12.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.73, compared to a current price of €11.50 — trading 48.8% above its estimated fair value. The current Quick Ratio is 3.84, which is 70% below median its 10-year median of 12.61 and 7% above the Biotechnology industry median of 3.59. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current Quick Ratio is 3.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?
Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued.
The current stock price of €11.50 is trading 48.8% above its estimated GF Value™ of €7.73.
GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for STU:9EP:
Quick Ratio: 3.84 (70% below median its 10-year median of 12.61)
GF Value™: €7.73 vs. price of €11.50 (48.8% above fair value)
Industry Position: 7% above the Biotechnology median (#681 of 1411)
No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score
Get the complete analysis for STU:9EP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9EP has been successfully added to your 
